ATE260261T1 - Oligobenzimidazolderivate und ihre verwendung als dna-transfektionsmittel - Google Patents

Oligobenzimidazolderivate und ihre verwendung als dna-transfektionsmittel

Info

Publication number
ATE260261T1
ATE260261T1 AT00976109T AT00976109T ATE260261T1 AT E260261 T1 ATE260261 T1 AT E260261T1 AT 00976109 T AT00976109 T AT 00976109T AT 00976109 T AT00976109 T AT 00976109T AT E260261 T1 ATE260261 T1 AT E260261T1
Authority
AT
Austria
Prior art keywords
nucleic acids
group
dna transfection
transfection agents
vivo
Prior art date
Application number
AT00976109T
Other languages
English (en)
Inventor
Daniel Scherman
Michel Bessodes
Bruno Pitard
Javier Soto
Gerardo Byk
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9913934A external-priority patent/FR2800736B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE260261T1 publication Critical patent/ATE260261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT00976109T 1999-11-05 2000-11-06 Oligobenzimidazolderivate und ihre verwendung als dna-transfektionsmittel ATE260261T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9913934A FR2800736B1 (fr) 1999-11-05 1999-11-05 Derives d'oligobenzimidazoles, les compositions les contenant et leurs utilisations
US17464800P 2000-01-05 2000-01-05
PCT/FR2000/003087 WO2001032630A1 (fr) 1999-11-05 2000-11-06 Derives d'oligobenzimidazoles et leur utilisation comme agents de transfection d'adn

Publications (1)

Publication Number Publication Date
ATE260261T1 true ATE260261T1 (de) 2004-03-15

Family

ID=26235148

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00976109T ATE260261T1 (de) 1999-11-05 2000-11-06 Oligobenzimidazolderivate und ihre verwendung als dna-transfektionsmittel

Country Status (12)

Country Link
EP (1) EP1230223B1 (de)
JP (1) JP2003513078A (de)
AT (1) ATE260261T1 (de)
AU (1) AU1399801A (de)
CA (1) CA2389778A1 (de)
DE (1) DE60008573T2 (de)
DK (1) DK1230223T3 (de)
ES (1) ES2211644T3 (de)
IL (1) IL149153A0 (de)
MX (1) MXPA02004449A (de)
PT (1) PT1230223E (de)
WO (1) WO2001032630A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320627D0 (en) * 2003-09-03 2003-10-01 Imp College Innovations Ltd Methods
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207393A (en) * 1983-08-05 1987-03-31 Neal Lloyd First Staining dna in living cells
NZ239893A (en) * 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell

Also Published As

Publication number Publication date
WO2001032630A1 (fr) 2001-05-10
AU1399801A (en) 2001-05-14
CA2389778A1 (fr) 2001-05-10
ES2211644T3 (es) 2004-07-16
IL149153A0 (en) 2002-11-10
MXPA02004449A (es) 2002-09-02
PT1230223E (pt) 2004-07-30
EP1230223A1 (de) 2002-08-14
JP2003513078A (ja) 2003-04-08
DK1230223T3 (da) 2004-06-14
EP1230223B1 (de) 2004-02-25
DE60008573T2 (de) 2004-12-16
DE60008573D1 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
DE50100893D1 (de) Verfahren zur Herstellung von 3,4-Alkylendioxythiophen-2,5-dicarbonsäurederivaten
TR199800602A2 (xx) Dithiolan t�revleri, haz�rlanmalar� ve terap�tik etkileri.
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
EA199901047A1 (ru) Жидкие производные бензизохинолина
PL327466A1 (en) Novel derivatives of barbituric acid, method of obtaining them and pharmaceutic agents containing such compounds
AU8997898A (en) Epoxysuccinamide derivatives
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
EP1288275A3 (de) Electrochrome Lösung, enthaltend eine Hydrazonverbindung und mit dieser hergestellte Vorrichtung
AU626095B2 (en) Hydroxyalkane carboxylic acid derivatives, their production and use
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
DE60008573D1 (de) Oligobenzimidazolderivate und ihre verwendung als dna-transfektionsmittel
MX2009005782A (es) Derivados de pirano, procedimiento de preparacion y uso de los mismos en perfumeria y saborizantes.
HUP0301258A2 (hu) Aminoizokinolincsoportot tartalmazó trombin inhibitorok és alkalmazásuk gyógyszerkészítmények előállítására
MEP12408A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
HUP0000275A2 (hu) Fenantridiniumszármazékok, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények
BG108423A (en) Dihydroimidazo[5,1-a]beta-carboline derivatives, method for preparing same and use thereof as medicine
DE69301639D1 (de) Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung
ATE160571T1 (de) 5-(1-fluorovinyl)-1h-pyrimidin-2,4-dion-derivat als antineoplastische mittel
AU2002321381A1 (en) Method for preparing organic, in particular lithocholic acid, nanotubes and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1230223

Country of ref document: EP

REN Ceased due to non-payment of the annual fee